NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

CervoMed Inc. (CRVO) Stock Analysis

CervoMed Inc. (CRVO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CRVO

$2.34

+$0.05 (+2.18%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRVO with… →

CRVO Key Statistics

As of Oct 21, 2026
Trading
Open
$2.31
Previous Close
$2.29
Day's Range
2.31–2.41
52-Week Range
2.13–10.00
Volume
78.28K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−4.30
Valuation
Market Cap
$35.38M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
106.79
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.21
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.97M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.12M
1-Year Return
−67.59%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
286.90K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CRVO closed at $2.34, −67.59% over 1 year.

CervoMed Inc. (CRVO) has a market capitalization of $35.38M.

In fiscal 2025, CRVO reported revenue of $0.00.

CRVO Stock Return by Calendar Year

CervoMed Inc. (CRVO) 10-year return: what $10,000 became

1 year
$10,000 $3,241
−67.59%
5 years
$10,000 $664
−93.36%
10 years
$10,000 $3
−99.97%

If you had invested $10,000 in CervoMed Inc. (CRVO) 10 years ago, at the close on October 21, 2016, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −54.92% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−70.38%
2025+237.61%
2024−69.33%
2023+0.53%
2022−67.35%
2021−61.25%
2020+73.91%
2019−76.88%
2018−88.76%
2017−47.79%
2016 (partial year)−71.75%

As of October 21, 2026.

CRVO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.97M—
2024$0.00−$16.29M—
2023$0.00−$2.17M—
2022$0.00−$5.80M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$28.29M−$26.97M—
2024$0.00—−$18.23M−$16.29M—
2023$0.00—−$7.81M−$2.17M—
2022$0.00—−$3.48M−$5.80M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRVO Valuation vs Biotechnology Median

Median of 608 stocks
MetricCRVOBiotechnology medianvs median
P/S ratio106.7913.308.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CervoMed Inc. (CRVO) carries a market capitalisation of $35.38M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 15.

Over the past 52 weeks the price has ranged from $2.13 to $10.00. The most recent close on file for CRVO is $2.34, dated October 21, 2026. That is +$0.05 (+2.18%) against the previous close. The latest close sits 9.86% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $26.97M. Earnings per share on a trailing basis come to −3.21.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 106.79 times revenue. On price-to-sales that is 8 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −67.59%. Across 10 years the annualized return works out at −54.92%. The reported beta is −4.3. Daily returns over the trailing 10 years annualize to a volatility of 145.86%.

Growth & Income

The record shows no dividend for CRVO.

The strongest complete calendar year on file is 2025 at +237.61%; the weakest is 2018 at −88.76%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −70.38%.

Peer Comparison

CervoMed Inc. (CRVO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CervoMed Inc. CRVO $35.38M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. CervoMed Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Visit website →